dr koff on the role of covalent btk inhibitors and pirtobrutinib in mcl
Published 1 month ago • 35 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:56
dr. rule on the role of btk inhibitors in mcl
-
1:47
dr. leslie on the role of btk inhibitors in relapsed/refractory mcl
-
1:56
updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
-
2:12
pirtobrutinib for btk inhibitor-naïve and btk inhibitor pre-treated r/r mcl
-
59:49
rebooting the btk inhibitor sequence in mcl
-
1:51
updates on the phase i/ii bruin study and the role of pirtobrutinib in mcl
-
1:16
dr. patel on differences between btk inhibitors in mcl
-
2:23
efficacy of pirtobrutinib in patients with r/r mcl previously treated with a covalent btki
-
5:59
differentiating btk inhibitor mechanisms of action in mcl
-
2:16
dr. ruan discusses btk inhibitors in mcl
-
1:32
selecting btk inhibitors for patients with mcl
-
1:09
dr. cohen on the potential of btk inhibitors in frontline treatment of mcl
-
1:08
phase i/ii bruin study: pirtobrutinib in patients intolerant to a covalent btk inhibitor
-
7:11
selection of a btk inhibitor in relapsed/refractory mcl
-
4:13
mcl: novel btk inhibitor combination strategies
-
1:05
dr. fenske on the utility of next-generation btk inhibitors in mcl
-
2:00
dr. goy discusses btk inhibitors in mcl
-
1:52
dr. eyre on btk inhibitors in combination with venetoclax for mcl
-
1:07
current state of the field: non-covalent btk inhibitors for cll